SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabets quarterly results sparked debate over softer Search and advertising growth and heavy AI infrastructure spending, which pushed free cash flow negative despite Google Cloud revenue more than doubling. Traders are split between viewing the cash burn and rising future capex as reasons for concern and treating the selloff as a buying opportunity given strong cloud growth and the companys longer-term AI prospects.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNows mixed quarterly results and softer fourth-quarter contracted-growth outlook have driven a sharp selloff, despite stronger revenue and a raised AI target. Traders are split between viewing the reaction as an overdone response to a modest earnings miss and seeing the outlook slowdown, high valuation, and AI-related software risks as reasons for caution.

Alphabet Inc - Ordinary Shares - Class C

Alphabets earnings miss and heavy AI infrastructure spending, which pressured cash flow, drove the selloff. Traders are divided over whether uncertain returns on AI investment and search competition outweigh strong cloud growth, with some seeing the decline as a buying opportunity.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances announcement of positive Phase 2 lifileucel data in previously treated metastatic non-small cell lung cancer, with a webcast to discuss the results and its precision-medicine strategy, is driving attention. Traders are largely enthusiastic about expanding the TIL therapy beyond melanoma, while speculation about a short squeeze and the results significance remains unconfirmed.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Alphabets earnings miss and heavy AI-investment concerns dominated discussion of QQQ, with traders debating whether the results signal broader pressure on tech or create a buying opportunity; strong Microsoft results offered a counterpoint. The Feds rate decision and upcoming inflation data also added to uncertainty.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Reports that Marvell is in advanced talks to acquire Lumentum are driving attention, though no deal is final. Traders are split between optimism about a potential takeover and skepticism about the rumor and how Marvell could finance a transaction, fueling sharp volatility.

Fortinet, Inc. provides cybersecurity solutions to a variety of businesses, such as enterprises, communication service providers, government organizations, and small to medium-sized businesses. Its product portfolio includes network security, secure access service edge, enterprise networking, security operations, application security, and operational technology. The company was founded by Ken Xie and Michael Xie in November 2000 and is headquartered in Sunnyvale, CA.

Fortinet Inc

Fortinets quarterly results triggered a sharp selloff despite beating headline estimates and raising its overall outlook; traders focused on slowing product growth, weaker service-revenue guidance, and gross-margin pressure against high expectations. The community is split between calling the drop an overreaction and viewing it as a valuation reset, while the decline also weighed on other cybersecurity stocks.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsofts quarterly results topped expectations, with accelerated Azure growth and stronger cloud guidance driving an initially positive reaction. Traders debated whether the AI and cloud momentum outweighed lower-than-expected capital spending and weaker free cash flow, while some noted that the after-hours gains faded.

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Bausch Health Companies Inc

Bausch Healths better-than-expected third-quarter results and raised outlook are driving the rally, with traders also noting a share-repurchase authorization. The reaction is broadly bullish, though some see the move as a swing trade and remain cautious about the companys substantial debt and whether gains will hold.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFis stronger-than-expected Q3 results and raised outlook are driving attention, with traders pointing to accelerating growth and analyst upgrades as support for the post-earnings rally. Bulls see elevated short interest as potential fuel for further gains, while skeptics question the valuation and warn the move could fade.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

US Reclassifies Weed: Can Cannabis ETFs Give Your Portfolio a New High? 

 Medical marijuana's US reclassification revives cannabis ETFs like WEED, with tax relief and reform hopes fueling sharp gains across the sector.

AdvisorShares Issues Statement on Finalization of Federal Cannabis Rescheduling

AdvisorShares Issues Statement on Finalization of Federal Cannabis Rescheduling AdvisorShares Issues Statement on Finalization of Federal Cannabis Rescheduling PR Newswire BETHESDA, Md., April 23...

TLRY Stock Drops Premarket: Why Analysts Are Mixed Despite Upbeat Q3 Report 

Equity

Tirlay Brands shares have declined 33% year to date.


Tilray To Produce And Distribute Carlsberg Beer Brands In US – Stock Gains 4%

The multi-year licensing agreement with the Danish brewing giant will allow Tilray to produce and distribute several Carlsberg beer brands in all U.S. channels starting Jan. 1, 2027. 


TLRY Stock In Focus After Alliance Global Halves Price Target

Alliance Global cut TLRY’s target price to $10 from $20, citing limited visibility into the company’s long-term sales trajectory and cash flow.

Cannabis ETFs Soar Double-Digits on Friday: Here's Why

Cannabis ETFs explode on reform buzz. CNBS, WEED, MSOS and MJ jumped double-digits on Dec. 12, 2025 as Trump reportedly weighs reclassifying marijuana, boosting optimism.

Trump Moves A Step Closer To Reclassifying Marijuana As A Less Dangerous Drug — A Breakout Moment For Weed Industry?

The cannabis industry is enjoying renewed momentum under Trump, whose administration has adopted a notably more accommodative approach toward the drug and its related products.

Tilray, IIPR, Trulieve, Other Cannabis Stocks Rally On Report Of Government Considering Adding CBD Treatment For Medicare Patients  

The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare. 

The Zacks Analyst Blog Highlights MSOS, CNBS, WEED, MJ and YOLO

Zacks Analyst Blog highlights MSOS, CNBS, WEED, MJ, and YOLO as marijuana ETFs soar over 100% in three months on U.S. legalization hopes and investor optimism.

From Loss to Lift-Off: Marijuana ETFs Rebound on Legalization Prospects 

Marijuana ETFs, such as WEED, MSOS, and CNBS, are rebounding as hopes for rescheduling boost investor optimism. 

Advisorshares Trust - AdvisorShares Pure Cannabis ETF

Neutral Sentiment

<ul class="summary-bullets"><li>Roth Capital upgraded its rating on TRLY to ‘Overweight,’ while Alliance Global maintained ‘neutral.’</li><li>Last year, the U.S. tightened rules on hemp-derived THC products, and now various states are also restricting or banning those products.</li><li>On Wednesday, Tirlay reported fiscal third-quarter results.</li></ul>Tilray Brands, Inc.’s third-quarter report drew a mixed reaction from Wall Street, as analysts balanced improving business fundamentals against looming regulatory shifts that could disrupt the marijuana industry.TLRY shares declined 1.5% in early premarket trading on Thursday, following a 5% dip the previous session.Alliance Global lowered its price target on TLRY to $7 from $9 (14% upside projection), while keeping a ‘Neutral’ rating, citing uncertainty over hemp restrictions.In November, the U.S. government tightened hemp regulations by capping&nbsp;total levels of tetrahydrocannabinol (THC) — the primary psychoactive component in cannabis that produces a “high”&nbsp;— at 0.3%, while also restricting products such as Delta-8, effectively curbing many intoxicating hemp items, including edibles, vapes, and beverages. Last month, Texas added further pressure by banning smokable hemp products and raising licensing fees, with more states expected to follow suit.On the other hand, Roth Capital upgraded its rating on TLRY to ‘Buy’ from ‘Neutral’ with an unchanged $10 price target.&nbsp; The research firm praised Tilray’s upbeat results, particularly the Canadian and international segments. Tilray shares are back at July 2025 levels, but the fundamental outlook has improved, and the potential for regulatory change is greater, the firm added.<h2 class="st-heading-2">Q3 Results Recap</h2>Revenue rose 19% to $206.7 million, helped by sharp growth in international sales, and came in higher than the $201.3 million expectation. Net loss narrowed significantly to $25.2 million from $793.5 million a year earlier. On an adjusted basis, loss per share of $0.24 missed the analyst target of $0.14.Tilray said international sales increased 73%, while its Tilray Pharma segment grew 34%. The company reaffirmed its outlook for fiscal 2026 core earnings of $62 million to $72 million.<h2 class="st-heading-2">Retail, Analyst View On TLRY</h2>On Stocktwits, retail sentiment for TLRY shifted from ‘bullish’ to ‘bearish’ following the results.&nbsp;“$TLRY Slow and steady wins the race. It sure ain't Nvidia, but I'll take it. Slight dip in margins, amid a sea of price compression. Revenue beat, and earnings meet. Not bad,”&nbsp;<a href="https://stocktwits.com/davidjbenz/message/649151732">said</a> a user.To be sure, traders are trading stock in anticipation of the U.S. potentially classifying marijuana as a Schedule III (S3) drug, indicating that it has a lesser potential for abuse and is allowed for use in specific medical treatment.Marijuana remains a Schedule I drug under federal law — the same category as heroin and LSD – a classification reserved for substances deemed to have high abuse potential and no accepted medical use. Weed stocks, including TLRY, rallied sharply in December after President Donald Trump announced&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-moves-a-step-closer-to-reclassifying-marijuana-as-a-less-dangerous-drug-a-breakout-moment-for-weed-industry/cLICa8WREFB">plans to reclassify</a>. It hasn’t happened yet.“Even without S3 record results, why are people so sad,”&nbsp;<a href="https://stocktwits.com/Tradefun1979/message/649157581">said</a> another Stocktwits user. “S3 is bonus but currently co. Is not doing bad, actually stellar results. I am buying and will hold Long term, very cheap now.”Meanwhile, Wall Street is in a wait-and-watch mode. Currently, seven out of 10 analysts have a ‘Hold’ rating on the stock, two rate it ‘Buy’, and one&nbsp;rates it ‘Strong Sell’, per Koyfin. Their average price target of $11.14 implies an over 80% upside from the stock’s last close.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

In this photo illustration, a Tilray Brands logo is seen displayed on a smartphone and in the background.

Tirlay Brands shares have declined 33% year to date.

Amplify Seymour Cannabis ETF

Tilray Brands Inc

AdvisorShares Pure Cannabis ETF

Yes, the bottom is in

No, more downside ahead

Too early to tell

Depends on the stock

Neocloud stocks like $NBIS, $CRWV, $IREN, and $APLD are rebounding after a brutal October. Have they bottomed?

Feed

News

Sentiment

Fundamentals

Info

YOLO AdvisorShares Pure Cannabis ETF

Fundamentals

Latest YOLO News